• 1. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 2. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 3. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873

Research Update on 4-Fluoro-5-methylnicotinonitrile (CAS: 1807299-17-7) in Chemical Biology and Pharmaceutical Applications

4-Fluoro-5-methylnicotinonitrile (CAS: 1807299-17-7) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and medicinal chemistry. This heterocyclic nitrile derivative, characterized by its fluorine and methyl substitutions on the pyridine ring, exhibits unique physicochemical properties that make it a valuable intermediate in the synthesis of bioactive molecules. Recent studies have focused on its role as a building block for kinase inhibitors, antiviral agents, and other therapeutic compounds targeting protein-protein interactions.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of 4-Fluoro-5-methylnicotinonitrile as a key precursor in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized the compound's nitrile group for strategic functionalization, enabling the development of potent and selective inhibitors with improved pharmacokinetic profiles. The fluorine atom at the 4-position was found to enhance binding affinity through favorable interactions with hinge region residues, while the methyl group at the 5-position contributed to metabolic stability.

In the field of antiviral research, a recent patent application (WO2023052345) disclosed the use of 4-Fluoro-5-methylnicotinonitrile derivatives as potential inhibitors of SARS-CoV-2 main protease. The compound's scaffold was modified to incorporate various pharmacophores, resulting in molecules with nanomolar inhibitory activity. Molecular docking studies revealed that the fluorinated pyridine core interacts with key catalytic residues, while the nitrile group forms a covalent bond with the active site cysteine, mimicking the natural substrate.

From a synthetic chemistry perspective, several innovative methodologies have been developed for the efficient preparation of 4-Fluoro-5-methylnicotinonitrile. A 2024 publication in Organic Letters described a novel palladium-catalyzed cyanation protocol that significantly improves the yield and purity of the compound compared to traditional methods. This advancement is particularly important for scaling up production to meet the growing demand in pharmaceutical development.

The compound's potential extends beyond small-molecule therapeutics. Recent work published in Chemical Science explored its application in the development of PROTACs (Proteolysis Targeting Chimeras), where 4-Fluoro-5-methylnicotinonitrile derivatives served as warheads for targeted protein degradation. The researchers successfully demonstrated selective degradation of oncogenic proteins in cellular models, opening new avenues for cancer therapy.

As research progresses, the unique properties of 4-Fluoro-5-methylnicotinonitrile continue to reveal new applications. Current investigations are exploring its use in fluorescent probes for biological imaging, as well as in the development of covalent inhibitors for challenging therapeutic targets. With its versatile chemistry and demonstrated biological activity, this compound remains at the forefront of innovative drug discovery efforts.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)